Maharaj, M.;                     Perrone, E.;                     Wirtz, R.M.;                     Heslop, L.;                     Govender, T.;                     Korowlay, N.A.;                     Ghai, K.;                     Parkar, T.;                     Baum, R.P.    
        Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders. Cancers 2025, 17, 476.
    https://doi.org/10.3390/cancers17030476
    AMA Style
    
                                Maharaj M,                                 Perrone E,                                 Wirtz RM,                                 Heslop L,                                 Govender T,                                 Korowlay NA,                                 Ghai K,                                 Parkar T,                                 Baum RP.        
                Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders. Cancers. 2025; 17(3):476.
        https://doi.org/10.3390/cancers17030476
    
    Chicago/Turabian Style
    
                                Maharaj, Masha,                                 Elisabetta Perrone,                                 Ralph M. Wirtz,                                 Lucille Heslop,                                 Trisha Govender,                                 Nisaar A. Korowlay,                                 Kriti Ghai,                                 Tanay Parkar,                                 and Richard P. Baum.        
                2025. "Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders" Cancers 17, no. 3: 476.
        https://doi.org/10.3390/cancers17030476
    
    APA Style
    
                                Maharaj, M.,                                 Perrone, E.,                                 Wirtz, R. M.,                                 Heslop, L.,                                 Govender, T.,                                 Korowlay, N. A.,                                 Ghai, K.,                                 Parkar, T.,                                 & Baum, R. P.        
        
        (2025). Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders. Cancers, 17(3), 476.
        https://doi.org/10.3390/cancers17030476